No Photo Available

Last Update


This profile was last updated on .

Is this you? Claim your profile.

Wrong Donald Marvin?

Mr. Donald R. Marvin

President and Chief Executive Officer

Inocucor Technologies Inc

Direct Phone: (303) ***-****       

Email: d***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Inocucor Technologies Inc

7220 Frederick-Banting Suite 100

Montreal, Quebec H4S 2A1


Company Description

Inocucor Technologies Inc., based in Montreal, is an ag biotech company that develops sustainable biological products for agriculture targeting the phyto-microbiome-the seeds, plants, root systems and the soil surrounding them. Inocucor's first-generation ... more

Find other employees at this company (22)

Background Information

Employment History

Chief Executive Officer and President

IdentiGEN Ltd.


President and Chief Executive Officer
Cairn Associates Inc

Board Member
Microbiome Therapeutics LLC

Board Member

Board Member
Melior Discovery Inc

VentureTalk Radio

Board Member
Tepnel Life Sciences PLC

Co-Founder, Chief Financial Officer and Senior Vice President of Corporate Development
Orchid Cellmark Inc

Board Member
NuMe Health LLC

Nasdaq-quoted Orchid Biosciences




Ohio State University



The Ohio State University


organizational behavior and finance

Iona College

Web References (159 Total References)

Don Marvin, President & CEO, ... [cached]

Don Marvin, President & CEO, INOCUCOR, USA

Inocucor President and CEO Donald ... [cached]

Inocucor President and CEO Donald R. Marvin announced results of the field trials during a presentation recently at Agri Innovation Forum in Winnipeg, Manitoba....

Donald Marvin, Inocucor ... [cached]

Donald Marvin, Inocucor president and CEO, tells GAI News that the double nod from the Canadian Food Inspection Agency was two years in the making. "With these approvals we can move forward with the commercialization of the company's Synergro Free product targeting commodity row crops this coming growing season. Synergro, our product for high-value produce, we can begin selling immediately," said Marvin, adding that the company has back orders to fill.

Andree-Lise M├ęthot, founder and managing partner of Montreal-based Cycle Capital Management, an early investor in Inocucor, tells GAI News Cycle was initially responsible for bringing Marvin, a transplant from the pharmaceutical industry, to the company.
In addition to Marvin, Cycle introduced the company to Jim Blome, chief executive at Bayer CropScience, who also chairs Inocucor's Board of Directors.
"Don has an amazing team around him, very savvy people in the ag sector, in [intellectual property] in terms of genetics and other things. He put together a team and it works very well with his investors including Cycle Capital and the people that we bring in, and I think he is really personally committed," she said.
"Independent studies have shown increased yields in strawberries of 30 percent or more," said Marvin, adding that yields for other high-value produce crops using a Synergro-based treatment program have jumped anywhere from the high-single digits to between 40 and 50 percent, depending on the particular crop.
We are pleased with the results," said Marvin.
Plus they have limited tools in their toolbox to treat crops because they are organic farmers," said Marvin, adding that when conventional growers began noticing the yield pops among their organic peers they too starting asking for the product.
That's how we do it in the U.S.," said Marvin.
Marvin also anticipates that the pair of U.S.-based family offices that backed the company in June 2016 also may commit additional capital for the Series B.
The lead investor in the Series B round, however, will be a first-time investor in Inocucor. "They will likely be joined by another new investor or two to fully complete the Series B financing," said Marvin, adding that he expects to make a formal announcement in the coming weeks.
The privately held company is not yet profitable as Inocucor continues to plow revenue from the sale of its products back into the business. Marvin expects, however, that in the next couple of years Inocucor will indeed become profitable. Meanwhile, revenue growth from 2016 to 2017 is pegged at 75 percent to 80 percent of the previous year given the wider distribution and international expansion ahead.
A lot is going on in the soybean area for us," said Marvin, adding that the company's Western Europe expansion is expected to be in Spain's high-value produce market. "Bio-stimulants are well accepted and adapted in Western Europe and also heavily used in Spain's high-value produce growing regions," he noted.
Indeed, part of the growth strategy at Inocucor for capturing market share is by strategic M&A, and depending on the timing Marvin could be seated on either side of the deal table. "You will see us make acquisitions along the way in the specialty ag biologicals space to drive market leadership in this rapidly growing sector," said Marvin.
As for an exit strategy, the end game could be one of several possibilities said Marvin, including a potential sale to a strategic buyer. "There is a lot of value to build under the curve, and we're in it for the long run. While we have very patient investors, at some point you have to give all stakeholders a pattern of liquidity and for me it's really a clinical process one goes through to achieve that objective," said Marvin, adding that there's no rush on the company's part to get there.

Through the company's proprietary ... [cached]

Through the company's proprietary fermentation process, these microbial products and their active bio-molecules give farmers new tools that naturally improve soil health and increase crop yields," said Donald R. Marvin, president and CEO of Inocucor.

Marvin said Inocucor has documented four years of enhanced yield increases and improved soil health through field trials and demonstrations conducted with commercial partners and customers in the U.S. and Canada.

MBT in the News | Microbiome Therapeutics [cached]

MBT Board Member Donald Marvin Named CEO of Inocucor Technologies

Similar Profiles

Other People with this Name

Other people with the name Marvin

Paul Marvin
chubb ltd

Catherine Marvin
Community Health Systems Inc.

Jason Marvin
Forte Advertising , LLC

Robert Marvin
University of Illinois at Chicago

David Marvin
Marvin & Palmer

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory